Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane

Toxicology Letters

Volumn 230, Issue 3, 2014, Pages 479-486

  Hunakova, Luba ^a   Gronesova, Paulina ^a   Horvathova, Eva ^a   Chalupa, Ivan ^a   Cholujova, Dana ^a   Duraj, Jozef ^a   Sedlak, Jan ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

Chromosomal aberrations; Cisplatin; Cytotoxicity, human ovarian carcinoma cells; Nrf 2 pathway; Sulforaphane

Indexed keywords

CISPLATIN; SULFORAPHANE; ANTINEOPLASTIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; NFE2L2 PROTEIN, HUMAN; SULFORAFAN; TRANSCRIPTION FACTOR NRF2;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CHROMOSOME ABERRATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; MODULATION; OVARY CARCINOMA; COMET ASSAY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; COMET ASSAY; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOTHIOCYANATES; NF-E2-RELATED FACTOR 2; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84910058318     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.08.018     Document Type: Article

References (29)

1. Bartkowiak D., Hogner S., Baust H., Nothdurft W., Rottinger E.M. Comparative analysis of apoptosis in HL60 detected by annexin-V and fluorescein-diacetate. Cytometry 1999, 37:191-196.
2. Burrell R.A., McClelland S.E., Endesfelder D., Groth P., Weller M.C., Shaikh N., Domingo E., Kanu N., Dewhurst S.M., Gronroos E., Chew S.K., Rowan A.J., Schenk A., Sheffer M., Howell M., Kschischo M., Behrens A., Helleday T., Bartek J., Tomlinson I.P., Swanton C. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013, 494:492-496.
3. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
4. Chou T.C. Theoretical basis experimental design , and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
5. Duesberg P., Stindl R., Hehlmann R. Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:14295-14300.
6. Duesberg P., Stindl R., Hehlmann R. Origin of multidrug resistance in cells with and without multidrug resistance genes: chromosome reassortments catalyzed by aneuploidy. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11283-11288.
7. Duraj J., Pastorek M., Vitkovska J., Cholujova D., Gronesova P., Hunakova L., Sedlak J. Proteasome inhibition leads to altered signaling in the proteome of cisplatin-resistant human ovarian carcinoma cell line. Neoplasma 2013, 60:627-634.
8. Fikrova P., Stetina R., Hrnciarik M., Rehacek V., Jost P., Hronek M., Zadak Z. Detection of DNA crosslinks in peripheral lymphocytes isolated from patients treated with platinum derivates using modified comet assay. Neoplasma 2013, 60:413-418.
9. Fimognari C., Berti F., Iori R., Cantelli-Forti G., Hrelia P. Micronucleus formation and induction of apoptosis by different isothiocyanates and a mixture of isothiocyanates in human lymphocyte cultures. Mutat. Res. 2005, 582:1-10.
10. Garrido N., Perez-Martos A., Faro M., Lou-Bonafonte J.M., Fernandez-Silva P., Lopez-Perez M.J., Montoya J., Enriquez J.A. Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. Biochem. J. 2008, 414:93-102.
11. Hunakova L., Bodo J., Chovancova J., Sulikova G., Pastorekova S., Sedlak J. Expression of new prognostic markers peripheral-type benzodiazepine receptor and carbonic anhydrase IX, in human breast and ovarian carcinoma cell lines. Neoplasma 2007, 54:541-548.
12. Huq F., Yu J.Q., Beale P., Chan C., Arzuman L., Nessa M.U., Mazumder M.E. Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer. Anticancer Res. 2014, 34:541-545.
13. Standing Commitee on Human Cytogenetic Nomenclature ISCN 1995: An International System for Human Cytogenetic Nomenclature: Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature 1995, 114. Karger medical and Scientific Publishers. F. Mitelman (Ed.).
14. Lee A.J., Endesfelder D., Rowan A.J., Walther A., Birkbak N.J., Futreal P.A., Downward J., Szallasi Z., Tomlinson I.P., Howell M., Kschischo M., Swanton C. Chromosomal instability confers intrinsic multidrug resistance. Cancer Res. 2011, 71:1858-1870.
15. McClelland S.E., Burrell R.A., Swanton C. Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy. Cell Cycle 2009, 8:3262-3266.
16. McGranahan N., Burrell R.A., Endesfelder D., Novelli M.R., Swanton C. Cancer chromosomal instability: therapeutic and diagnostic challenges. EMBO Rep. 2012, 13:528-538.
17. Miller D.M., Singh I.N., Wang J.A., Hall E.D. Administration of the Nrf2-ARE activators sulforaphane and carnosic acid attenuates 4-hydroxy-2-nonenal-induced mitochondrial dysfunction ex vivo. Free Radic. Biol. Med. 2013, 57:1-9.
18. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
19. Pappa G., Bartsch H., Gerhauser C. Biphasic modulation of cell proliferation by sulforaphane at physiologically relevant exposure times in a human colon cancer cell line. Mol. Nutr. Food Res. 2007, 51:977-984.
20. Pfuhler S., Wolf H.U. Detection of DNA-crosslinking agents with the alkaline comet assay. Environ. Mol. Mutagen. 1996, 27:196-201.
21. Piberger A.L., Koberle B., Hartwig A. The broccoli-born isothiocyanate sulforaphane impairs nucleotide excision repair: XPA as one potential target. Arch. Toxicol. 2014, 88:647-658.
22. Safaei R., Larson B.J., Cheng T.C., Gibson M.A., Otani S., Naerdemann W., Howell S.B. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells. Mol. Cancer Ther. 2005, 4:1595-1604.
23. Sampath D., Plunkett W. Design of new anticancer therapies targeting cell cycle checkpoint pathways. Curr. Opin. Oncol. 2001, 13:484-490.
24. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
25. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988, 175:184-191.
26. Slamenova D., Gabelova A., Ruzekova L., Chalupa I., Horvathova E., Farkasova T., Bozsakyova E., Stetina R. Detection of MNNG-induced DNA lesions in mammalian cells; validation of comet assay against DNA unwinding technique alkaline elution of DNA and chromosomal aberrations. Mutat. Res. 1997, 383:243-252.
27. Steinmetz K.A., Potter J.D. Vegetables fruit and cancer prevention: a review. J. Am. Diet. Assoc. 1996, 96:1027-1039.
28. Venitt S., Parry J.M. Mutagenicity Testing. A Practical Approach 2014, 217-221. IRL Press, Oxford and Washington.
29. Wernyj R.P., Morin P.J. Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist. Updat. 2004, 7:227-232.